Strides ‘Evaluating’ Mylan Claims Over Factory Lapses Cited By FDA
This article was originally published in PharmAsia News
Drug firm Strides Shasun Ltd says it is "evaluating" claims from Mylan Inc involving US Food and Drug Administration complaints about three plants that the Indian company sold to the global generics drug giant as part of a high-profile $1.75bn deal two years ago.
You may also be interested in...
For the last few years, Indian generic companies have been making headlines for all the wrong reasons, rapped by the US Food and Drug Administration over problems ranging from fudged test results to poor-quality manufacturing standards. But lately, the firms have been enjoying a run of good regulatory tidings, giving a fillip to their share prices.
Asia’s biggest biotech company, India’s Biocon Ltd, has announced it will conduct what it says is the first-ever clinical trial of a siRNA therapy in India with US partner Quark, is aimed at tackling a rare eye condition.
Prime Minister Narendra Modi’s government has decided to "comprehensively review" India's antiquated drug legislation to take into account the latest medical developments and improve safety, amid complaints about poor-quality manufacturing and products.